Miralax

Constipation, Exophthalmos, Bowel preparation therapy + 8 more

Treatment

3 FDA approvals

20 Active Studies for Miralax

What is Miralax

Polyethylene glycol

The Generic name of this drug

Treatment Summary

Polyethylene glycol (PEG) is a synthetic polymer made from ethylene glycol molecules joined by an ether linkage. Depending on the molecular weight, PEGs can be liquids or waxy solids. The most common types are PEG 3350 and PEG 400. PEGs have different applications in medical and industrial fields. PEG 3350 is an over-the-counter osmotic laxative used to treat constipation, and PEG 3350 is also used to cleanse the colon before a colonoscopy. PEGs are useful in gastroenterology because they have strong water-binding capacity

GoLYTELY

is the brand name

image of different drug pills on a surface

Miralax Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

GoLYTELY

Polyethylene glycol

1984

207

Approved as Treatment by the FDA

Polyethylene glycol, also known as GoLYTELY, is approved by the FDA for 3 uses such as Constipation and Constipation .

Constipation

Constipation

Constipation

Effectiveness

How Miralax Affects Patients

PEG 3350 causes diarrhea by increasing the amount of water in the intestines. Effects usually start within 1-2 hours after taking it. When used to prepare for a colonoscopy, it is often combined with electrolytes to prevent dehydration. Over-the-counter versions of PEG 3350 do not contain any salts that can be absorbed. Studies have shown that it does not affect the ability of the intestines to absorb fluids or create and maintain electrochemical gradients.

How Miralax works in the body

Osmotic laxatives contain substances that draw water into the large intestine, making the stool softer and easier to pass. One such substance is polyethylene glycol, which binds to water molecules and causes them to accumulate in the colon. This accumulation leads to looser stools.

When to interrupt dosage

The recommended dosage of Miralax is contingent upon the diagnosed disorder, such as Dry Eye Syndrome, Bowel preparation therapy and Chronic Constipation. The quantity of dosage may deviate, depending on the method of delivery outlined in the table hereunder.

Condition

Dosage

Administration

Dry Eye Syndrome

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Colon Cleansing for Colonoscopy

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Constipation

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Colonoscopy

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Constipation

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Exophthalmos

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Dry Eye Syndrome

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Bowel preparation therapy

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Chronic Constipation

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Obesity

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Eye

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel - Nasal, Gel, Kit; Powder, for solution; Tablet, delayed release - Oral, Nasal, Spray, Gel - Topical, Solution, Solution - Oral, Liquid - Oral, Powder - Topical, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Spray - Nasal, Kit - Oral, Kit, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Kit - Oral; Topical, Oral; Topical, Nasogastric, Powder, for solution - Nasogastric, Oral; Rectal, Powder, for suspension, Kit; Powder, for solution; Tablet, delayed release, Spray, metered, Spray, metered - Nasal, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic

Warnings

Miralax Contraindications

Condition

Risk Level

Notes

Toxic colitis

Do Not Combine

Intestinal Perforation

Do Not Combine

Megacolon, Toxic

Do Not Combine

Gastric Retention

Do Not Combine

Gastrointestinal obstruction

Do Not Combine

Ileus

Do Not Combine

There are 20 known major drug interactions with Miralax.

Common Miralax Drug Interactions

Drug Name

Risk Level

Description

Bisacodyl

Major

The risk or severity of mucosal ulceration and ischemic colitis can be increased when Polyethylene glycol is combined with Bisacodyl.

Bisoxatin

Major

The risk or severity of mucosal ulceration and ischemic colitis can be increased when Polyethylene glycol is combined with Bisoxatin.

Dantron

Major

The risk or severity of mucosal ulceration and ischemic colitis can be increased when Polyethylene glycol is combined with Dantron.

Deacetylbisacodyl

Major

The risk or severity of mucosal ulceration and ischemic colitis can be increased when Polyethylene glycol is combined with Deacetylbisacodyl.

Oxyphenisatin

Major

The risk or severity of mucosal ulceration and ischemic colitis can be increased when Polyethylene glycol is combined with Oxyphenisatin.

Miralax Toxicity & Overdose Risk

The lowest toxic dose of PEG 3350 in rats has been found to be 22000 mg/kg. Too much PEG 3350 may cause diarrhea, and those who overdose should be given supportive treatments to help with their symptoms.

image of a doctor in a lab doing drug, clinical research

Miralax Novel Uses: Which Conditions Have a Clinical Trial Featuring Miralax?

67 active clinical trials are being conducted to determine the utility of Miralax in providing Bowel preparation therapy, Body weight >20kg and Exophthalmos relief.

Condition

Clinical Trials

Trial Phases

Exophthalmos

2 Actively Recruiting

Phase 2, Phase 3

Constipation

17 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Phase 3

Constipation

0 Actively Recruiting

Colon Cleansing for Colonoscopy

0 Actively Recruiting

Eye

0 Actively Recruiting

Chronic Constipation

1 Actively Recruiting

Not Applicable

Dry Eye Syndrome

8 Actively Recruiting

Phase 1, Phase 4, Not Applicable, Phase 2, Phase 3

Bowel preparation therapy

1 Actively Recruiting

Phase 1, Phase 2

Obesity

0 Actively Recruiting

Dry Eye Syndrome

6 Actively Recruiting

Phase 4, Not Applicable, Phase 2

Colonoscopy

3 Actively Recruiting

Not Applicable

Miralax Reviews: What are patients saying about Miralax?

5

Patient Review

8/14/2022

Miralax for Incomplete or Infrequent Bowel Movements

I've had chronic constipation since childhood and it's only gotten worse as I've aged. Miralax is a lifesaver that helps me avoid severe symptoms on a daily basis.

5

Patient Review

10/1/2022

Miralax for Incomplete or Infrequent Bowel Movements

I've had IBS for over 30 years, and this is the best treatment I've ever found. Thank you, Marilax!

5

Patient Review

12/13/2019

Miralax for Emptying of the Bowel

This medication helped me heal my fissure quickly and effectively.

4.7

Patient Review

9/4/2019

Miralax for Incomplete or Infrequent Bowel Movements

I've been trying different treatments for my constipation for many years now, and Miralax seems to be doing the best job. I'm using it daily in combination with magnesium citrate, and so far so good.

4

Patient Review

8/25/2021

Miralax for Incomplete or Infrequent Bowel Movements

I take this medication every day without any issues. It's very effective and I'm 74 years old.

4

Patient Review

2/4/2019

Miralax for Incomplete or Infrequent Bowel Movements

The product works well, but I have difficulty holding and measuring the dosage from the container.

3.7

Patient Review

12/30/2021

Miralax for Incomplete or Infrequent Bowel Movements

This medication does help, but I often feel nauseous after taking it.

2.7

Patient Review

8/18/2019

Miralax for Incomplete or Infrequent Bowel Movements

I experienced some very severe and unpleasant side effects after taking only one dose of this product. I ended up in the emergency room with cramping, dizziness, nausea, back pain, and more. Thankfully, the CT scan and blood tests came back normal. However, I will definitely be looking for a different constipation remedy in the future.

2.3

Patient Review

9/1/2018

Miralax for Incomplete or Infrequent Bowel Movements

I had some bad abdominal pains after taking this medication for a few days, as prescribed by my doctor. I'm going to look for something else because chronic constipation is an issue for me and I'm getting older.

1.7

Patient Review

7/31/2018

Miralax for Incomplete or Infrequent Bowel Movements

While this drug did help with my constipation issue, the back pain it caused was unbearable. I stopped taking it and will never go near it again.

1

Patient Review

4/18/2020

Miralax for Incomplete or Infrequent Bowel Movements

I experienced severe stomach pain and rectal bleeding after taking this drug. Additionally, I was incredibly dizzy and did not have a single bowel movement. I believe that a class action lawsuit should be filed against the company for their sale of this dangerous, untested drug.

1

Patient Review

11/9/2019

Miralax for Emptying of the Bowel

Unfortunately, this medication caused me a great deal of discomfort. I experienced hot flashes, cramps, and constipation. I stopped and started the medication three different times to be sure it was Miralax that was causing the problems, and it unfortunately was.

1

Patient Review

2/8/2022

Miralax for Emptying of the Bowel

I cannot recommend this medication. I began vomiting shortly after taking it as prescribed, and ended up having to cancel my colonoscopy because I couldn't keep the medicine down. This was a terrible experience all around.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about miralax

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is MiraLAX a stool softener or laxative?

"MiraLAX is a laxative that works by drawing water into the colon, which softens the stool and may stimulate the colon to contract. These actions help ease bowel movements. Colace is a stool softener."

Answered by AI

How long does it take for MiraLAX to make you poop?

"MiraLAX typically causes bowel movements to begin within an hour of consumption, but this may differ for some people. There is no need to be concerned if you do not have a bowel movement after drinking the first half of the MiraLAX, simply continue to drink liquids and consume the second half as directed."

Answered by AI

How much does MiraLAX make you poop?

"You can start taking MiraLAX when you first notice constipation, and continuing taking it once a day until you're relieved of constipation (up to 7 days maximum, or as directed by your doctor)."

Answered by AI

What does MiraLAX do to you?

"The purpose of this medication is to treat constipation that occurs occasionally. It does this by causing the stool to retain water which then softens the stool and increases the number of bowel movements. This medication is classified as an osmotic-type laxative."

Answered by AI

Clinical Trials for Miralax

Image of Eye Research Foundation /ID# 267931 in Newport Beach, United States.

ABBV-444 for Dry Eye Syndrome

18+
All Sexes
Newport Beach, CA

Dry Eye Disease (DED) refers to a long-term condition that happens when there is not enough lubrication in your eyes. This can happen when your eye cannot make enough tears or if you make poor-quality tears. The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (ABBV-444) with Refresh Optive UD for 90 days in participants with Dry Eye Disease (DED. ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). Participants will be placed into 1 of 2 treatment arms. Each group receives different treatment. Adult participants diagnosed with dry eye disease will be enrolled. Around 250 participants will be enrolled in the study at approximately 20 sites across the US In this study, participants first complete a 7-day run-in period using REFRESH PLUS® eye drops. Those eligible are then randomized to receive ABBV-444 eye drops or REFRESH OPTIVE® Unit Dose eye drops. Participants in both arms will receive treatment for a 90-day treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend multiple required study visits during the study at the study site. The effect of the treatment will be checked by medical assessments and questionnaires.

Phase 3
Recruiting

Eye Research Foundation /ID# 267931 (+6 Sites)

ABBVIE INC.

AbbVie

Image of Center for Sight in Las Vegas, United States.

Acoltremon for Dry Eye Syndrome

18+
All Sexes
Las Vegas, NV

Dry eye disease (DED) is a common, chronic and multifactorial disease of the ocular surface presenting with signs and symptoms of ocular discomfort, visual disturbance and fluctuation, tear film instability, ocular surface inflammation and damage. It significantly affects patients' quality of life and is one of the most frequent reasons for visits to eye care providers. Many patients remain symptomatic in real-world settings despite current pharmacologic therapeutic options available. As symptoms often lag behind ocular signs, a 3 month study with multiple time points has been designed to assess short term and mid-term symptomatic changes. This study will use Dry Eye Surveys to evaluate Acoltremon in Real World Settings to help understand its real world effectiveness and potential to improve symptoms in dry eye patients.

Phase 4
Waitlist Available

Center for Sight

Image of Kannar Eye Care in Pittsburg, United States.

Acoltremon for Dry Eye Syndrome

18 - 75
All Sexes
Pittsburg, KS

This 1-month, 3-visit study will be conducted at the Southern College of Optometry (Memphis, TN), Kannarr Eye Care, LLC (Pittsburg, KS) and Complete Eye Care of Medina (Minneapolis, MN). Adults ≥18 years of age who have been diagnosed with DED for at least 6 months and who are currently symptomatic (Eye Dryness VAS Score ≥40) will be recruited. Subjects will have an abnormal Schirmer test of \<10 mm/5 min. Subjects will also be required to score ≤70 on the IDEEL Quality of Life (QoL) Work domain to ensure that their DED symptoms are significantly impacting their ability to do work.9 Subjects will be required to have corrected distance visual acuity of 20/32 (0.2 logMAR) or better.

Phase 4
Recruiting

Kannar Eye Care (+2 Sites)

Have you considered Miralax clinical trials?

We made a collection of clinical trials featuring Miralax, we think they might fit your search criteria.
Go to Trials

Have you considered Miralax clinical trials?

We made a collection of clinical trials featuring Miralax, we think they might fit your search criteria.
Go to Trials

Have you considered Miralax clinical trials?

We made a collection of clinical trials featuring Miralax, we think they might fit your search criteria.
Go to Trials